Trial · NCT00245102

Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma

NCT00245102, Phase 2, Completed, National Cancer Institute (NCI); results first posted 2014-01-20

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma. Trials, record NCT00245102. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00245102

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma
NCT number: NCT00245102
Status: Completed
Phases: Phase 2
Enrollment: 147 participants, actual
Lead sponsor: National Cancer Institute (NCI)
Conditions: Adult Angiosarcoma, Adult Epithelioid Sarcoma, Adult Leiomyosarcoma, Adult Malignant Fibrous Histiocytoma, Adult Neurofibrosarcoma, Adult Synovial Sarcoma, Ovarian Sarcoma, Recurrent Adult Soft Tissue Sarcoma, Recurrent Uterine Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage III Uterine Sarcoma, Stage IV Adult Soft Tissue Sarcoma, Stage IV Uterine Sarcoma, Uterine Carcinosarcoma, Uterine Leiomyosarcoma
Interventions: sorafenib tosylate
First posted: 2005-10-27
Last updated: 2014-05-23
Results first posted: 2014-01-20

Source ClinicalTrials.gov

Registered outcomes1

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Overall Response Rate Measured by Complete Response (CR) Rate and Partial Response (PR) Rate as Determined by RECIST	Up to 4 weeks	A 5% response rate is considered not promising, a 20% response rate is considered promising. For each stratum, the response rate will be estimated and a confidence interval will be constructed.

Source ClinicalTrials.gov

Outcomes1

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Overall Response Rate Measured by Complete Response (CR) Rate and Partial Response (PR) Rate as Determined by RECIST	Up to 4 weeks		participants	NUMBER

Source ClinicalTrials.gov

Results by group12

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Units
Overall Response Rate Measured by Complete Response (CR) Rate and Partial Response (PR) Rate as Determined by RECIST	Angiosarcoma	Complete Response	1	participants
Overall Response Rate Measured by Complete Response (CR) Rate and Partial Response (PR) Rate as Determined by RECIST	MPNST	Complete Response	0	participants
Overall Response Rate Measured by Complete Response (CR) Rate and Partial Response (PR) Rate as Determined by RECIST	Leiomyosarcoma	Complete Response	0	participants
Overall Response Rate Measured by Complete Response (CR) Rate and Partial Response (PR) Rate as Determined by RECIST	Undifferentiated Pleomorphic Sarcoma	Complete Response	0	participants
Overall Response Rate Measured by Complete Response (CR) Rate and Partial Response (PR) Rate as Determined by RECIST	Fibrosarcoma	Complete Response	0	participants
Overall Response Rate Measured by Complete Response (CR) Rate and Partial Response (PR) Rate as Determined by RECIST	Other Histology	Complete Response	0	participants
Overall Response Rate Measured by Complete Response (CR) Rate and Partial Response (PR) Rate as Determined by RECIST	Angiosarcoma	Partial Response	4	participants
Overall Response Rate Measured by Complete Response (CR) Rate and Partial Response (PR) Rate as Determined by RECIST	MPNST	Partial Response	0	participants
Overall Response Rate Measured by Complete Response (CR) Rate and Partial Response (PR) Rate as Determined by RECIST	Leiomyosarcoma	Partial Response	1	participants
Overall Response Rate Measured by Complete Response (CR) Rate and Partial Response (PR) Rate as Determined by RECIST	Undifferentiated Pleomorphic Sarcoma	Partial Response	0	participants

1 to 10 of 12Source ClinicalTrials.gov

See all 12 results by group

Participant flow18

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Angiosarcoma	44
Overall Study	STARTED	MPNST	16
Overall Study	STARTED	Leiomyosarcoma	46
Overall Study	STARTED	Undifferentiated Pleomorphic Sarcoma	13
Overall Study	STARTED	Fibrosarcoma	5
Overall Study	STARTED	Other Histology	23
Overall Study	COMPLETED	Angiosarcoma	37
Overall Study	COMPLETED	MPNST	12
Overall Study	COMPLETED	Leiomyosarcoma	39
Overall Study	COMPLETED	Undifferentiated Pleomorphic Sarcoma	10

1 to 10 of 18Source ClinicalTrials.gov

See all 18 participant flow

Adverse events582

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Alanine aminotransferase increased	Investigations	Angiosarcoma	3	44	3
other	Alanine aminotransferase increased	Investigations	MPNST	1	16	1
other	Alanine aminotransferase increased	Investigations	Leiomyosarcoma	5	46	5
other	Alanine aminotransferase increased	Investigations	Undifferentiated Pleomorphic Sarcoma	2	13	2
other	Alanine aminotransferase increased	Investigations	Fibrosarcoma	1	5	1
other	Alanine aminotransferase increased	Investigations	Other Histology	1	23	1
other	Aspartate aminotransferase increased	Investigations	Angiosarcoma	3	44	3
other	Aspartate aminotransferase increased	Investigations	MPNST	1	16	1
other	Aspartate aminotransferase increased	Investigations	Leiomyosarcoma	4	46	4
other	Aspartate aminotransferase increased	Investigations	Undifferentiated Pleomorphic Sarcoma	0	13	0

1 to 10 of 582Source ClinicalTrials.gov

See all 582 adverse events

Adverse event totals18

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Angiosarcoma
Total, all-cause mortality	MPNST
Total, all-cause mortality	Leiomyosarcoma
Total, all-cause mortality	Undifferentiated Pleomorphic Sarcoma
Total, all-cause mortality	Fibrosarcoma
Total, all-cause mortality	Other Histology
Total, other adverse events	Angiosarcoma	36	44
Total, other adverse events	MPNST	12	16
Total, other adverse events	Leiomyosarcoma	40	46
Total, other adverse events	Undifferentiated Pleomorphic Sarcoma	10	13

1 to 10 of 18Source ClinicalTrials.gov

See all 18 adverse event totals

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants1

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

Project	Title	Principal investigators	Organization	Funder	Fiscal years
P30CA008748	Cancer Center Support Grant	Rudin, Charles M.	SLOAN-KETTERING INST CAN RESEARCH	NATIONAL CANCER INSTITUTE	1985 to 2026

Source NIH RePORTER

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00245102

GET https://conductscience.org/api/trials/v1/NCT00245102/events?page=2

API reference For AI assistants